Sepp De Raedt (Chief Technology Officer & Co-founder - DoMore Diagnostics)
ArticleAI and the future of biomarker analysis in early R&D
AI is transforming biomarker analysis in early drug discovery, revealing hidden biological patterns that improve target discovery, patient selection and trial design for more precise and predictive R&D.